Literature DB >> 2055694

Contractile responses of isolated bovine retinal microarteries to acetylcholine.

A M Hoste1, L J Andries.   

Abstract

The contractile responses of isolated and activated bovine retinal microarteries (BRA) (diameter, 204 +/- 4 microns; n = 48) to acetylcholine (ACh) were studied. These responses depended on the nature of the activating agent. The ACh relaxed BRA activated by prostaglandin F2 alpha (PGF2 alpha) and circumferential stretching in a dose-dependent manner but had no significant effect on K(+)-activated BRA. The effects of ACh also depended on the degree of BRA activation: the stronger the PGF2 alpha-induced contractions, the weaker the relaxation produced by ACh. In equivalent PGF2 alpha-induced contractions, the ACh effects were reproducible. The muscarinic antagonist, atropine, reversed the relaxation caused by ACh of PGF2 alpha-activated BRA. Physostigmine, an inhibitor of acetylcholinesterase, did not potentiate or prolong the relaxant action of ACh. Selective removal of the BRA endothelium (by gassing the BRA lumen, checked by scanning electron microscopy) blocked the relaxation caused by ACh of PGF2 alpha-induced contractions and unmasked a constricting action of ACh. This suggests that, in BRA with functional endothelium, the direct constricting effects of ACh on smooth muscle are masked by the more potent dilating activity, mediated by endothelial muscarinic receptors. Acetylcholinesterase was not found in BRA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2055694

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

Review 1.  Leveraging Optogenetic-Based Neurovascular Circuit Characterization for Repair.

Authors:  Elena Ivanova; Christopher W Yee; Botir T Sagdullaev
Journal:  Neurotherapeutics       Date:  2016-04       Impact factor: 7.620

Review 2.  Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures.

Authors:  Niall Patton; Tariq Aslam; Thomas Macgillivray; Alison Pattie; Ian J Deary; Baljean Dhillon
Journal:  J Anat       Date:  2005-04       Impact factor: 2.610

3.  Role of the M3 muscarinic acetylcholine receptor subtype in murine ophthalmic arteries after endothelial removal.

Authors:  Adrian Gericke; Andreas Steege; Caroline Manicam; Tobias Böhmer; Jürgen Wess; Norbert Pfeiffer
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-29       Impact factor: 4.799

4.  Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma.

Authors:  C Jui-Ling Liu; Y-C Ko; C-Y Cheng; J C Chou; W-M Hsu; J-H Liu
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

5.  Identification of the muscarinic acetylcholine receptor subtype mediating cholinergic vasodilation in murine retinal arterioles.

Authors:  Adrian Gericke; Jan J Sniatecki; Evgeny Goloborodko; Andreas Steege; Olga Zavaritskaya; Jan M Vetter; Franz H Grus; Andreas Patzak; Jürgen Wess; Norbert Pfeiffer
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-27       Impact factor: 4.799

6.  The effect of latanoprost on ocular blood flow.

Authors:  Alon Harris; Hanna J Garzozi; Lynne McCranor; Ehud Rechtman; Chi-Wah Yung; Brent Siesky
Journal:  Int Ophthalmol       Date:  2008-02-23       Impact factor: 2.031

7.  The α₁B -adrenoceptor subtype mediates adrenergic vasoconstriction in mouse retinal arterioles with damaged endothelium.

Authors:  Tobias Böhmer; Caroline Manicam; Andreas Steege; Martin C Michel; Norbert Pfeiffer; Adrian Gericke
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

8.  Optogenetic Stimulation of Cholinergic Amacrine Cells Improves Capillary Blood Flow in Diabetic Retinopathy.

Authors:  Elena Ivanova; Paola Bianchimano; Carlo Corona; Cyril G Eleftheriou; Botir T Sagdullaev
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-08-03       Impact factor: 4.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.